Here is the design of a clinical trial:

Official Title: Targeting Human Milk Fortification to Improve Preterm Infant Growth and Brain Development

Included conditions:
- Preterm Birth
- Breast Milk Expression
- Nutrition Disorder, Infant
- Brain Development Abnormality
- Neurodevelopmental Disorders

Study Armgroups:
- {'label': 'Standard fortification', 'type': 'NO_INTERVENTION', 'description': 'Standard of care fortification with multicomponent human milk fortifier (24 kcal/oz) and liquid protein (0.27 g/dL); additional protein and/or calories added only for growth faltering.'}
- {'label': 'Individually targeted fortification', 'type': 'EXPERIMENTAL', 'description': 'Standard of care fortification plus extra protein and/or calories to ensure that "base" milk has protein 1 g/dL and calories 67/dL.', 'interventionNames': ['Other: Individually targeted fortification']}

Interventions:
- {'type': 'OTHER', 'name': 'Individually targeted fortification', 'description': 'Abbott liquid protein and/or medium chain triglyceride are added routinely to ensure that the "base" milk has protein 1 g/dL and calories 67/dL.', 'armGroupLabels': ['Individually targeted fortification']}

Primary Outcomes:
- {'measure': 'Weight', 'description': 'Weight z-score', 'timeFrame': "at study endpoint (36 weeks' postmenstrual age or discharge)"}
- {'measure': 'Length', 'description': 'Length z-score', 'timeFrame': "at study endpoint (36 weeks' postmenstrual age or discharge)"}
- {'measure': 'Fat free mass', 'description': 'Fat free mass estimated with air displacement plethysmography (z-score)', 'timeFrame': "at study endpoint (36 weeks' postmenstrual age or discharge)"}
- {'measure': 'Total brain volume', 'description': 'Total brain volume by MRI', 'timeFrame': "at term equivalent age (38 to 41 weeks' postmenstrual age)"}
- {'measure': 'Cerebellar volume', 'description': 'Cerebellar volume by MRI', 'timeFrame': "at term equivalent age (38 to 41 weeks' postmenstrual age)"}
- {'measure': 'Bayley-III cognitive score', 'description': 'Scaled composite score (continuous), higher score indicates better performance, range of possible scores 55-145', 'timeFrame': "at 2 years' corrected age"}
- {'measure': 'Bayley-III motor score', 'description': 'Scaled composite score (continuous), higher score indicates better performance, range of possible scores 46-154', 'timeFrame': "at 2 years' corrected age"}

Please estimate the sample size based on the assumption: 
Significance level (α) = 0.05, power = 0.8, 5% attrition by NICU discharge, 5% loss due to uncorrectable motion artifact for MRI outcomes, 10% further attrition to 2 years' corrected age.
Sample size
        The planned sample size is 130 infants (65 per study group). Accounting for expected attrition (5% by NICU discharge due to death or unexpected transfer) and an additional 5% loss due to uncorrectable motion artifact for MRI outcomes, we expect to be able to detect a moderate effect of the intervention on primary outcomes (0.49 z-scores in weight, 0.24 z-scores in fat free mass, 24âcc total brain volume) at Î±â=â0.05 and power 0.8. Accounting for 10% further attrition to 2âyearsâ corrected age, we have adequate power to detect an 8.1-point difference between groups on the Bayley cognitive scale.